BRPI0715698B8 - produto, composição farmacêutica que o contém e uso de composto - Google Patents

produto, composição farmacêutica que o contém e uso de composto

Info

Publication number
BRPI0715698B8
BRPI0715698B8 BRPI0715698A BRPI0715698A BRPI0715698B8 BR PI0715698 B8 BRPI0715698 B8 BR PI0715698B8 BR PI0715698 A BRPI0715698 A BR PI0715698A BR PI0715698 A BRPI0715698 A BR PI0715698A BR PI0715698 B8 BRPI0715698 B8 BR PI0715698B8
Authority
BR
Brazil
Prior art keywords
compound
product
pharmaceutical composition
composition containing
pharmaceutically acceptable
Prior art date
Application number
BRPI0715698A
Other languages
English (en)
Inventor
Clozel Martine
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38954615&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0715698(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BRPI0715698A2 publication Critical patent/BRPI0715698A2/pt
Publication of BRPI0715698B1 publication Critical patent/BRPI0715698B1/pt
Publication of BRPI0715698B8 publication Critical patent/BRPI0715698B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

produto, composição farmacêutica que o contém e uso de composto a invenção refere-se a um produto que contém o composto da seguinte fórmula ( i) ou um sal farmaceuticamente aceitável deste composto, em combinação com pelo menos um composto dotado de propriedades inibidoras de pde5, ou um sal farmaceuticamente aceitável do mesmo, para uso terapêutico, simultaneamente, separadamente ou durante um período de tempo, no tratamento de uma enfermidade em que está envolvida vasoconstrição.
BRPI0715698A 2006-08-29 2007-08-28 produto, composição farmacêutica que o contém e uso de composto BRPI0715698B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IB2006052999 2006-08-29
IBPCT/IB06/052999 2006-08-29
IB2006053857 2006-10-19
IBPCT/IB06/053857 2006-10-19
PCT/IB2007/053448 WO2008026156A2 (en) 2006-08-29 2007-08-28 Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor

Publications (3)

Publication Number Publication Date
BRPI0715698A2 BRPI0715698A2 (pt) 2013-08-06
BRPI0715698B1 BRPI0715698B1 (pt) 2020-01-21
BRPI0715698B8 true BRPI0715698B8 (pt) 2021-05-25

Family

ID=38954615

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0715698A BRPI0715698B8 (pt) 2006-08-29 2007-08-28 produto, composição farmacêutica que o contém e uso de composto

Country Status (31)

Country Link
US (8) US8268847B2 (pt)
EP (1) EP2059246B1 (pt)
JP (1) JP5208113B2 (pt)
KR (1) KR101473022B1 (pt)
CN (1) CN101511365B (pt)
AR (1) AR062501A1 (pt)
AU (1) AU2007290099B2 (pt)
BR (1) BRPI0715698B8 (pt)
CA (1) CA2659770C (pt)
CL (1) CL2007002494A1 (pt)
CY (2) CY1114735T1 (pt)
DK (1) DK2059246T3 (pt)
ES (1) ES2438792T3 (pt)
FI (1) FIC20240045I1 (pt)
FR (1) FR24C1054I2 (pt)
HR (1) HRP20131233T1 (pt)
HU (1) HUS2400046I1 (pt)
IL (1) IL197235A (pt)
LT (1) LTPA2024537I1 (pt)
MA (1) MA30704B1 (pt)
MX (1) MX2009002057A (pt)
MY (1) MY154591A (pt)
NL (1) NL301308I2 (pt)
NO (1) NO342554B1 (pt)
NZ (1) NZ575702A (pt)
PL (1) PL2059246T3 (pt)
PT (1) PT2059246E (pt)
RU (1) RU2462249C2 (pt)
SI (1) SI2059246T1 (pt)
TW (1) TWI388556B (pt)
WO (1) WO2008026156A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1928409E (pt) 2005-09-12 2012-11-27 Actelion Pharmaceuticals Ltd Composição farmacêutica estável que compreende uma pirimidina-sulfamida
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
US8541433B2 (en) * 2008-02-20 2013-09-24 Actelion Pharmaceuticals, Ltd. Combination comprising macitentan and paclitaxel for treating multi-drug resistant ovarian cancer
LT2315587T (lt) 2008-08-13 2018-01-10 Actelion Pharmaceuticals Ltd. Terapinės kompozicijos, turinčios macitentano
TWI462739B (zh) * 2010-11-02 2014-12-01 Univ Kaohsiung Medical Ｓｉｌｄｅｎａｆｉｌ－同族物四級銨哌嗪鹽類之製備及醫療用途
CN102949395A (zh) * 2011-09-22 2013-03-06 荆志成 盐酸伐地那非片在制备治疗肺动脉高压药物中的应用
CN102839165B (zh) * 2012-09-26 2014-12-10 金普诺安生物科技（苏州）有限公司 基因突变型重组蛋白酶k及其工业化生产方法
CN104411691B (zh) * 2013-06-14 2016-05-25 杭州普晒医药科技有限公司 马西替坦晶体及其制备方法、其药物组合物和用途
KR20190030805A (ko) 2017-09-14 2019-03-25 경상대학교산학협력단 폐고혈압 예방 또는 치료용 흡입제, 및 이의 투여방법
CA3123990A1 (en) * 2018-12-21 2020-06-25 Actelion Pharmaceuticals Ltd Pharmaceutical composition for the treatment of pulmonary arterial hypertension
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
CN114728002A (zh) 2019-11-29 2022-07-08 埃科特莱茵药品有限公司 治疗肺动脉高血压的方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2801584A1 (de) * 1978-01-14 1979-07-19 Bayer Ag Halogensubstituierte pyrimidin (2)yl-thiono-thiol-phosphor(phosphon)- saeureester, verfahren zu ihrer herstellung und ihre verwendung als insektizide und akarizide
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW394761B (en) 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
US5589006A (en) * 1993-11-30 1996-12-31 Canon Kabushiki Kaisha Solar battery module and passive solar system using same
IL111959A (en) 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
WO1996016963A1 (de) 1994-11-25 1996-06-06 F. Hoffmann-La Roche Ag Sulfonamide und deren verwendung als heilmittel
TW313568B (pt) 1994-12-20 1997-08-21 Hoffmann La Roche
US5739333A (en) 1995-05-16 1998-04-14 Tanabe Seiyaku Co., Ltd. Sulfonamide derivative and process for preparing the same
WO1997022595A1 (en) 1995-12-20 1997-06-26 Yamanouchi Pharmaceutical Co., Ltd. Arylethenesulfonamide derivatives and drug composition containing the same
US6362178B1 (en) 1997-11-12 2002-03-26 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
TWI284642B (en) 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
DE60037308T2 (de) 1999-09-03 2008-10-30 Actelion Pharmaceuticals Ltd. Bis-sulfonamiden
TW200400821A (en) 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
CN1407973A (zh) 1999-12-22 2003-04-02 埃科特莱茵药品有限公司 丁炔二醇衍生物
AU2001263850A1 (en) 2000-04-20 2001-11-07 Actelion Pharmaceuticals Ltd Pyrimidine-sulfonamides having endothelin-antagonist activity
AU2001265871A1 (en) 2000-04-25 2001-11-07 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
HU229403B1 (en) * 2000-12-18 2013-12-30 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
DE10148883A1 (de) * 2001-10-04 2003-04-10 Merck Patent Gmbh Pyrimidinderivate
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US7094081B1 (en) * 2005-03-24 2006-08-22 Delphi Technologies, Inc. Electrical connector assembly
PT1928409E (pt) * 2005-09-12 2012-11-27 Actelion Pharmaceuticals Ltd Composição farmacêutica estável que compreende uma pirimidina-sulfamida
WO2007119214A2 (en) * 2006-04-13 2007-10-25 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis

Also Published As

Publication number Publication date
WO2008026156A3 (en) 2008-10-16
JP5208113B2 (ja) 2013-06-12
MA30704B1 (fr) 2009-09-01
RU2009111378A (ru) 2010-10-10
CY1114735T1 (el) 2017-01-25
HRP20131233T1 (hr) 2014-01-31
US20130210830A9 (en) 2013-08-15
EP2059246A2 (en) 2009-05-20
US20130005734A1 (en) 2013-01-03
US8268847B2 (en) 2012-09-18
NZ575702A (en) 2011-11-25
CA2659770A1 (en) 2008-03-06
TW200823198A (en) 2008-06-01
CN101511365B (zh) 2011-08-17
CY2024033I2 (el) 2026-02-25
IL197235A0 (en) 2009-12-24
LTPA2024537I1 (pt) 2025-01-10
BRPI0715698A2 (pt) 2013-08-06
TWI388556B (zh) 2013-03-11
RU2462249C2 (ru) 2012-09-27
AU2007290099B2 (en) 2013-01-31
HUS2400046I1 (hu) 2025-01-28
WO2008026156A2 (en) 2008-03-06
US20200038401A1 (en) 2020-02-06
PT2059246E (pt) 2013-12-16
MY154591A (en) 2015-06-30
HK1133597A1 (en) 2010-04-01
US20180147205A1 (en) 2018-05-31
US20140148460A1 (en) 2014-05-29
NO342554B1 (no) 2018-06-11
CL2007002494A1 (es) 2008-04-04
NL301308I2 (nl) 2024-12-30
FIC20240045I1 (fi) 2024-12-16
AR062501A1 (es) 2008-11-12
DK2059246T3 (da) 2013-12-02
FR24C1054I1 (fr) 2025-02-21
US20200352944A1 (en) 2020-11-12
CA2659770C (en) 2014-11-18
US20190083494A1 (en) 2019-03-21
CY2024033I1 (el) 2026-02-25
IL197235A (en) 2014-04-30
MX2009002057A (es) 2009-03-06
PL2059246T3 (pl) 2014-03-31
US20210177849A1 (en) 2021-06-17
EP2059246B1 (en) 2013-10-16
CN101511365A (zh) 2009-08-19
AU2007290099A1 (en) 2008-03-06
KR101473022B1 (ko) 2014-12-15
NO20091254L (no) 2009-03-26
BRPI0715698B1 (pt) 2020-01-21
ES2438792T3 (es) 2014-01-20
JP2010502588A (ja) 2010-01-28
SI2059246T1 (sl) 2014-01-31
FR24C1054I2 (fr) 2025-10-17
KR20090057009A (ko) 2009-06-03
US20090318459A1 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
BRPI0715698B8 (pt) produto, composição farmacêutica que o contém e uso de composto
ECSP088902A (es) Derivados de pirazolo[3,4-d]-pirimidina utiles para tratar trastornos respiratorios
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
MX341212B (es) Inhibidor de bromodominio de benzodiazepina.
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
MX384206B (es) Formulaciones de inhibidores de dpp iv
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
CY1116688T1 (el) Τροποποιητες φαρμακοκινητικων ιδιοτητων θεραπευτικων ειδων
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
BR112015023412A8 (pt) 3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante, sua composição farmacêutica e seu uso.
CL2007003604A1 (es) Composicion farmaceutica para administrar oral que comprende el compuesto 17-aminogeldanamicina amorfo; y su uso en el tratamiento del cancer.
TNSN08444A1 (en) Bicyclic derivatives as cetp inhibitors
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
ATE520668T1 (de) Sigmarezeptor-inhibitoren
EA200801997A1 (ru) Новые соединения
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
HN2008001666A (es) Derivados acidos de cicloalquilamino
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
MX2010007948A (es) Inhibidores de proteinas de apoptosis.
BRPI0618479A2 (pt) pirrolpiridinas composição farmacêutica que as contém
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
MA32841B1 (fr) Composés de cycloundeca depsipeptides et leur utilisation comme médicament
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
BRPI0606322A2 (pt) formulações intravenosas de inibidores de pde-5
MX2009013482A (es) Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/01/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/08/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF